Nicola Kenealy
BSc. Hons
Senior Trial Manager
I have been working in the Primary Care Clinical Trial Unit since May 2022, where I am a Senior Trial Manager overseeing the following studies:
- RESTED
- OPTIMISE X
- OPTIMISE 2
- SHIP
- TOUCAN
- SNAP2
Before joining Primary Care I worked at NDORMS for 8 years as a Trial Manager and before that for 3 years as a Trial Coordinator at OCTO.
Key publications
-
Home-based rehabilitation programme compared with traditional physiotherapy for patients at risk of poor outcome after knee arthroplasty: The CORKA randomised controlled trial
Journal article
Barker KL. et al, (2021), BMJ Open, 11
-
Outpatient physiotherapy versus home-based rehabilitation for patients at risk of poor outcomes after knee Arthroplasty: CORKA RCT
Journal article
Barker KL. et al, (2020), Health Technology Assessment, 24, 1 - 115
-
plaTform fOr Urinary tract infection diagnostiC evAluatioN (TOUCAN): a protocol for a prospective diagnostic accuracy study of point-of-care testing in patients suspected of acute uncomplicated urinary tract infection in primary care clinics in England
Journal article
Turner PJ. et al, (2025), BMJ Open, 15
-
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial
Journal article
Nanchahal J. et al, (2022), The Lancet Rheumatology, 4, e407 - e416
-
Effect of antihypertensive deprescribing on hospitalisation and mortality: long-term follow-up of the OPTiMISE randomised controlled trial
Journal article
Sheppard JP. et al, (2024), The Lancet Healthy Longevity, 5, e563 - e573
Recent publications
-
plaTform fOr Urinary tract infection diagnostiC evAluatioN (TOUCAN): a protocol for a prospective diagnostic accuracy study of point-of-care testing in patients suspected of acute uncomplicated urinary tract infection in primary care clinics in England
Journal article
Turner PJ. et al, (2025), BMJ Open, 15
-
Effect of antihypertensive deprescribing on hospitalisation and mortality: long-term follow-up of the OPTiMISE randomised controlled trial
Journal article
Sheppard JP. et al, (2024), The Lancet Healthy Longevity, 5, e563 - e573
-
Effect of antihypertensive deprescribing on serious adverse events, mortality, and cardiovascular disease: Long-term follow-up of the OPTiMISE randomised controlled trial
Journal article
SHEPPARD J. et al, (2024), The Lancet Healthy Longevity
-
EFFECT OF ANTIHYPERTENSIVE DEPRESCRIBING ON SERIOUS ADVERSE EVENTS, MORTALITY, AND CARDIOVASCULAR DISEASE: LONG-TERM FOLLOW-UP OF THE OPTIMISE RANDOMISED CONTROLLED TRIAL
Journal article
Sheppard J. et al, (2024), JOURNAL OF HYPERTENSION, 42
-
Anti-TNF (adalimumab) injection for the treatment of adults with frozen shoulder during the pain predominant stage protocol for a multi-centre, randomised, double blind, parallel group, feasibility trial
Journal article
Hopewell S. et al, (2023), NIHR Open Research, 2